Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HBI-002 in Healthy Volunteers
NCT03926819Phase 1Completed
- Sponsor
- Hillhurst Biopharmaceuticals
- Start
- Jul 2022
- Primary completion
- Apr 2023
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HBI-002 in sickle cell anemia (SCA) (2 arms), sponsored by Hillhurst Biopharmaceuticals. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) and Maximum Plasma Concentration (Cmax) up to 72 hours. Started Jul 2022; status: completed.
02
Drugs
HBI-002
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT03926819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926819.